7.09 USD
-0.24 (-3.27%)
7.15 USD
+0.06 (+0.85%)
ChartMill assigns a Buy % Consensus number of 54% to MYGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.13. This target is 14.73% above the current price.
MYGN was analyzed by 19 analysts. The buy percentage consensus is at 54. So analysts seem to be rather neutral about MYGN.
In the previous month the buy percentage consensus was at a similar level.
MYGN was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-04 | TD Cowen | Maintains | Hold -> Hold |
| 2025-11-04 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-21 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-05-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-08 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-07 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-05-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-09 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-04-01 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-03-12 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-03-04 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-03-03 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-02-25 | UBS | Maintains | Neutral -> Neutral |
| 2025-02-25 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-02-12 | Craig-Hallum | Initiate | Buy |
| 2025-01-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-16 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2024-12-13 | B of A Securities | Maintains | Underperform -> Underperform |
| 2024-12-10 | UBS | Initiate | Neutral |
| 2024-12-09 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-11-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-09-19 | Morgan Stanley | Initiate | Equal-Weight |
| 2024-08-27 | Wells Fargo | Initiate | Overweight |
| 2024-08-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
MYRIAD GENETICS INC / MYGN FAQ
What is the average price target for MYRIAD GENETICS INC (MYGN) stock?
19 analysts have analysed MYGN and the average price target is 8.13 USD. This implies a price increase of 14.73% is expected in the next year compared to the current price of 7.09.
How do analysts rate MYRIAD GENETICS INC (MYGN)?
The consensus rating for MYRIAD GENETICS INC (MYGN) is 53.6842 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for MYRIAD GENETICS INC stock?
The number of analysts covering MYRIAD GENETICS INC (MYGN) is 19.